We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    03665285
Previous Study | Return to List | Next Study

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03665285
Recruitment Status : Recruiting
First Posted : September 11, 2018
Last Update Posted : August 19, 2022
Sponsor:
Information provided by (Responsible Party):
NextCure, Inc.

Brief Summary:
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.

Condition or disease Intervention/treatment Phase
Advanced or Metastatic Solid Tumors Lung Cancer Breast Cancer Head and Neck Squamous Cell Carcinoma Endometrial Cancer Melanoma CRC Urothelial Carcinoma Cholangiocarcinoma Drug: NC318 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 187 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Actual Study Start Date : September 28, 2018
Estimated Primary Completion Date : December 15, 2023
Estimated Study Completion Date : December 15, 2023


Arm Intervention/treatment
Experimental: NC318
NC318 for IV infusion of various dose strengths administered in 14 day dosing cycles. Alternative dosing schedules may be explored once RP2D has been determined.
Drug: NC318
NC318 is an experimental antibody drug that may make the immune response more active against cancer.




Primary Outcome Measures :
  1. Number of participants with treatment-emergent Adverse Events as assessed by CTCAE v5.0 [ Time Frame: up to 14 months ]
    Frequency, duration, and severity of treatment-emergent adverse events (AEs)

  2. Define a maximum tolerated dose (MTD) or pharmacologically active dose (PAD) [ Time Frame: 28 days ]
    A 3 + 3 design will be utilized to determine the MTD of NC318


Secondary Outcome Measures :
  1. Disease Response as assessed by RECIST 1.1 [ Time Frame: up to 14 months ]
    Assessing objective response rate (ORR), duration of response (DoR), and disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

  2. Maximum Plasma Concentration (Cmax) of NC318 [ Time Frame: 14 weeks ]
    To evaluate the Maximum Plasma Concentration (Cmax) of NC318

  3. Area Under the Curve (AUC) of NC318 [ Time Frame: 14 weeks ]
    To evaluate the Area Under the Curve (AUC) of NC318

  4. Half-life (t1/2) of NC318 [ Time Frame: 14 weeks ]
    To evaluate the half-life (t1/2) of NC318



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women aged 18 or older.
  • Willingness to provide written informed consent for the study.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
  • Subjects with advanced unresectable and/or metastatic solid tumors.
  • Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. Note: There is no limit to the number of prior treatment regimens.
  • Presence of measurable disease based on RECIST v1.1. Tumor lesions situated in a previously irradiated area, or in an area subjected to other locoregional therapy, are not considered measurable unless there has been demonstrated progression in the lesion.
  • Able to provide pretreatment tumor tissue sample at Screening.
  • Subjects of childbearing potential (defined as female subjects who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy and are not postmenopausal, defined as ≥ 12 months of amenorrhea not caused by reversible conditions, diseases, or medications) and non-sterilized male subjects must agree to take appropriate precautions to avoid pregnancy or fathering children (with at least 99% certainty) from screening through 90 days after the last dose of study drug.

Exclusion Criteria:

  • Inability to comprehend or unwilling to sign the Informed Consent Form.
  • Screening laboratory values of:

    1. Absolute neutrophil count < 1.5 × 10^9/L
    2. Platelets < 100 × 10^9/L
    3. Hemoglobin < 9 g/dL or < 5.6 mmol/L
    4. Serum creatinine > 1.5 × institutional upper limit of normal (ULN)
    5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 × ULN
    6. Total bilirubin > 1.5 × ULN.
    7. International normalized ratio (INR) or prothrombin time (PT) > 1.5 × ULN or activated partial thromboplastin time (aPTT) > 1.5 × ULN
  • Transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 7 days before the first administration of study drug.
  • Receipt of anticancer medications or investigational drugs within the following intervals before the first administration of study drug:

    1. ≤ 14 days for chemotherapy, targeted small molecule therapy, or radiation therapy. Subjects must also not require chronic use of corticosteroids and must not have had radiation pneumonitis because of a treatment. A 1-week washout is permitted for palliative radiation to non-central nervous system (CNS) disease with medical monitor approval. Note: Bisphosphonates and denosumab are permitted medications.
    2. ≤ 28 days for prior immunotherapy or persistence of active cellular therapy (e.g., chimeric antigen receptor T cell therapy; other cellular therapies must be discussed with the medical monitor to determine eligibility).
    3. ≤ 28 days for a prior monoclonal antibody used for anticancer therapy except for denosumab.
    4. ≤ 7 days for immune-suppressive-based treatment for any reason. Note: Use of inhaled or topical steroids or corticosteroid use for radiographic procedures is permitted. Note: The use of physiologic corticosteroid replacement therapy may be approved after consultation with the medical monitor.
    5. ≤ 28 days or 5 half-lives (whichever is longer) before the first dose for all other investigational study drugs or devices. For investigational agents with long half-lives (e.g., > 5 days), enrollment before the fifth half-life requires medical monitor approval.
    6. ≤ 14 days for COVID-19 vaccine.
  • Has not recovered to ≤ Grade 1 from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy.
  • Receipt of a live vaccine within 30 days of planned start of study therapy.
  • Active autoimmune disease that required systemic treatment in the past (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).
  • Known active CNS metastases and/or carcinomatous meningitis.
  • Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry after treatment with curative intent.
  • Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.
  • Documented known activating or driver mutations (i.e. EGFR mutations/amplification, BRAF mutations, ALK alterations, etc.) which have not been previously treated with a standard of care targeted therapy.
  • History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful.
  • Uncontrolled systemic fungal, bacterial, viral, or other infection despite appropriate anti-infection treatment.
  • Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV), unless the hepatitis is considered to be cured.
  • Known history of HIV (HIV 1 or HIV 2 antibodies).
  • Known allergy or reaction to any component of study drug or formulation components.
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 90 days after the last dose of study treatment.
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03665285


Contacts
Layout table for location contacts
Contact: Director of Clinical Operations at NextCure, Inc. 240-763-0535 NCClin@NextCure.com
Contact: Director of Clinical Research (240) 399-4900 NelsonM@NextCure.com

Locations
Layout table for location information
United States, California
The Angeles Clinic and Research Institute Recruiting
Los Angeles, California, United States, 90025
Contact: Saba Mukarram    310-582-7900    SMukarram@theangelesclinic.org   
Principal Investigator: Omid Hamid, MD         
United States, Colorado
University of Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Maximilian DeKunffy    720-848-0669    maximilian.dekunffy@cuanschutz.edu   
Principal Investigator: Theresa Medina, MD         
United States, Connecticut
Yale University Cancer Center Completed
New Haven, Connecticut, United States, 06510
United States, Maryland
Luminis Health Anne Arundel Medical Center Recruiting
Annapolis, Maryland, United States, 21401
Contact: Venita Crawford    443-481-4393      
Principal Investigator: Young Lee, MD         
United States, Michigan
Michigan Center of Medical Research Recruiting
Farmington Hills, Michigan, United States, 48334
Contact: Alex Kurish    248-747-4383    alexandrea.kurish@michmer.com   
Principal Investigator: Savitha Balaraman, MD         
United States, New Jersey
John Theurer Cancer Center at Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Chelsea McCabe    551-996-5863    Chelsea.McCabe@hackensackmeridian.org   
Principal Investigator: Martin Gutierrez, MD         
United States, New York
Laura and Isaac Perlmutter Cancer Center Recruiting
New York, New York, United States, 10016
Contact: Elaine Shum, MD    212-731-5662      
Principal Investigator: Elaine Shum, MD         
Westchester Medical Center Recruiting
Valhalla, New York, United States, 10901
Contact: Zuheir Diab    917-589-2284    Zuheir.diab@wmchealth.org   
Principal Investigator: Daniel Cho, MD         
United States, Pennsylvania
Pennsylvania Cancer Specialists and Research Institute Recruiting
Gettysburg, Pennsylvania, United States, 17325
Contact: Vanessa Warner, CCRC    717-334-4033 ext 141    vrwarner@pcsri.com   
Contact: Terry Burke, RN,BSN    717-334-4033 ext 131    tburke@pcsri.com   
Principal Investigator: Satish A Shah, MD         
United States, Texas
NEXT Oncology Recruiting
San Antonio, Texas, United States, 78240
Contact: Cynthia De Leon    210-580-9521    cdeleon@nextoncology.com   
Principal Investigator: Anthony W. Tolcher, MD         
Sponsors and Collaborators
NextCure, Inc.
Investigators
Layout table for investigator information
Study Director: Han Myint, MD NextCure, Inc.
Layout table for additonal information
Responsible Party: NextCure, Inc.
ClinicalTrials.gov Identifier: NCT03665285    
Other Study ID Numbers: NC318-01
First Posted: September 11, 2018    Key Record Dates
Last Update Posted: August 19, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by NextCure, Inc.:
Advanced Cancer
Metastatic Cancer
NC318
Immunotherapy
PD-L1
Dose Escalation
Biomarker
PK
Cohort Expansion
Solid Tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Endometrial Neoplasms
Cholangiocarcinoma
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Squamous Cell
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Adenocarcinoma
Head and Neck Neoplasms